Home2019-01-04T19:16:45+00:00

We all have people close to us who have been affected by a neurodegenerative disease.

Amylyx is developing AMX0035 to improve the lives of people living with ALS, Alzheimer’s and other diseases of the brain.

Learn More

Areas of Focus

October 24, 2017

Innovative Alzheimer’s Disease Combination Therapy Trial Supported By New Joint Funding Initiative

Wave

The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation (ADDF) are collaborating to jointly fund a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.

Read More

September 19, 2017

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of ALS

Wave

Amylyx Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis (ALS).

Read More

September 7, 2017

Project ALS and Amylyx Enter Collaboration to Test AMX0035

Wave

Project ALS and Amylyx Pharmaceuticals today announced a collaboration to undertake pre-clinical studies with Amylyx’s oral compound AMX0035 to advance the understanding of the compound’s neurobiological effects.

Read More

Contact Us